atezolizumab
Marketed as TECENTRIQ.
FDA approval history
| FDA ID | Brand | Approval date | Manufacturer |
|---|---|---|---|
| BLA761034 | TECENTRIQ | 2016-05-18 | GENENTECH INC |
Manufacturers
GENENTECH INC
Common denial patterns
- Triple-negative breast cancer indication (voluntarily withdrawn 2021 — plans cite this for all TNBC denials)
- SCLC maintenance denial
- Off-label NSCLC combinations
Specific notes
Brand: Tecentriq. PD-L1 inhibitor. SubQ formulation (Tecentriq Hybreza) FDA-approved September 2024. Note: TNBC accelerated approval withdrawn August 2021 — be careful citing this indication in appeals.
Genentech Patient Foundation: https://www.gene.com/patients/patient-foundation
Frequently asked questions
Why does insurance commonly deny atezolizumab?
Triple-negative breast cancer indication (voluntarily withdrawn 2021 — plans cite this for all TNBC denials); SCLC maintenance denial; Off-label NSCLC combinations.
When was atezolizumab FDA approved?
Earliest FDA approval on record: 2016-05-18.
What brand names are sold as atezolizumab?
TECENTRIQ.
Is there a patient assistance program for atezolizumab?
Yes — Genentech Patient Foundation at https://www.gene.com/patients/patient-foundation.
What's specific to atezolizumab?
Brand: Tecentriq. PD-L1 inhibitor. SubQ formulation (Tecentriq Hybreza) FDA-approved September 2024. Note: TNBC accelerated approval withdrawn August 2021 — be careful citing this indication in appeals.
Related
Sources
Appeal a atezolizumab denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com